Sanofi Pasteur, maker of Gardasil, wins contract to supply cervical cancer vaccine in Ireland

Irish Medical Times

Gary Culliton

gary.culliton@imt.ie

The contract to supply a cervical cancer vaccine which has been awarded to Sanofi Pasteur, the Minister for Health, Mary Harney, confirmed at yesterday’s meeting of the Joint Oireachtas Committee on Health.

The vaccine, Gardasil, will be given to first-year students in second-level schools this year.

Gardasil protects against the HPV virus and also against genital warts. The announcement follows a two-week “cooling off” period after the contract was awarded.

Gardasil is the only cervical cancer vaccine that helps protect against four types of human papillomavirus (HPV): two types that cause 70 per cent of cervical cancer cases, and two more types that cause 90 per cent of genital warts cases.

Gardasil is aimed at girls and young women aged nine to 26.

Gardasil may not fully protect everyone, and does not prevent all types of cervical cancer, so it’s important to continue routine cervical cancer screenings, according to Gardasil.com. It is given as three injections over six months.

MORE…

GARDASIL IS NOT A CERVICAL CANCER VACCINE.  It only protects women from the viruses that cause cervical cancer.  Please note that if you already have HPV and get the vaccine your chances of getting cervical cancer increase by 44.6% (FDA)

PG

Author: Leslie Carol Botha

Author, publisher, radio talk show host and internationally recognized expert on women's hormone cycles. Social/political activist on Gardasil the HPV vaccine for adolescent girls. Co-author of "Understanding Your Mood, Mind and Hormone Cycle." Honorary advisory board member for the Foundation for the Study of Cycles and member of the Society for Menstrual Cycle Research.